Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Rises By 69.0%

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 71 shares, a growth of 69.0% from the May 14th total of 42 shares. Based on an average trading volume of 250 shares, the short-interest ratio is presently 0.3 days.

NewAmsterdam Pharma Price Performance

Shares of NAMSW stock traded down $0.00 on Wednesday, reaching $18.70. 652 shares of the company’s stock were exchanged, compared to its average volume of 1,926. NewAmsterdam Pharma has a 52 week low of $7.80 and a 52 week high of $30.45. The company’s fifty day simple moving average is $22.70 and its 200 day simple moving average is $22.69.

Institutional Investors Weigh In On NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 15,708 shares of the company’s stock, valued at approximately $397,000.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.